AGONIST AND ANTAGONIST EFFECTS OF DYNORPHIN A-(1-13) IN A THERMAL ANTINOCICEPTION ASSAY IN RHESUS-MONKEYS

被引:0
|
作者
BUTELMAN, ER
FRANCE, CP
WOODS, JH
机构
[1] UNIV MICHIGAN,DEPT PSYCHOL,ANN ARBOR,MI 48109
[2] LOUISIANA STATE UNIV,MED CTR,DEPT PHARMACOL & EXPTL THERAPEUT,NEW ORLEANS,LA
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The agonist and antagonist effects of intravenously administered dynorphin A-(1- 13) were characterized in the warm water (50 and 55 degrees C) tail withdrawal assay of antinociception in rhesus monkeys. The peptide dose-dependently elevated tail withdrawal latencies in 50 degrees C water, but was ineffective in 55 degrees C water. The antinociceptive effect of dynorphin was surmountably antagonized by quadazocine (0.1 mg/kg) and nor-binaltorphimine (3.2 mg/kg), but was not antagonized by clocinnamox (0.1 mg/kg); this pattern of antagonism is consistent with a kappa-opioid receptor mediated effect. Pretreatment with dynorphin A-(1-13) (0.0323.2 mg/kg) antagonized the antinociceptive effects of U50,488 and U69,593 in 55 degrees C water, suggesting a low efficacy action of the peptide at the receptors activated by these kappa agonists. However, dynorphin A-(1-13) (3.2 mg/kg) did not antagonize other kappa agonists: bremazocine (0.018-0.056 mg/kg) and enadoline (0.0056-0.018 mg/kg). Taken together, these dynorphin A-(1-13) findings support the notion of functional kappa-opioid receptor subtypes, and it appears that dynorphin A-(1 -13) has limited efficacy at one of these sites. Finally, dynorphin A-(1-13) (0.32 mg/kg) also antagonized the antinociceptive effects of the mu-agonist etonitazene (0.0018-0.01 mg/kg).
引用
收藏
页码:374 / 380
页数:7
相关论文
共 50 条
  • [32] PREFERRED CONFORMATION, ORIENTATION, AND ACCUMULATION OF DYNORPHIN A-(1-13)-TRIDECAPEPTIDE ON THE SURFACE OF NEUTRAL LIPID-MEMBRANES
    ERNE, D
    SARGENT, DF
    SCHWYZER, R
    BIOCHEMISTRY, 1985, 24 (16) : 4261 - 4263
  • [33] Effects of the kappa-opioid dynorphin A(1-13) on learning and memory in mice
    Ukai, M
    Itoh, J
    Kobayashi, T
    Shinkai, N
    Kameyama, T
    BEHAVIOURAL BRAIN RESEARCH, 1997, 83 (1-2) : 169 - 172
  • [34] NONOPIOID EFFECTS OF DYNORPHIN A(1-13) ON THE FETAL PITUITARY-ADRENAL AXIS
    TAYLOR, CC
    SOONG, Y
    WU, DL
    YEE, WJ
    SZETO, HH
    FASEB JOURNAL, 1995, 9 (03): : A100 - A100
  • [35] DYNORPHIN A-(1-13) POTENTLY IMPROVES THE IMPAIRMENT OF SPONTANEOUS-ALTERNATION PERFORMANCE INDUCED BY THE MU-SELECTIVE OPIOID RECEPTOR AGONIST DAMGO IN MICE
    ITOH, J
    UKAI, M
    KAMEYAMA, T
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1994, 269 (01): : 15 - 21
  • [36] AN AVIDIN BIOTIN BASED ENZYME-LINKED-IMMUNOSORBENT-ASSAY FOR DYNORPHIN-A 1-13
    HOCHHAUS, G
    HU, L
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1990, 8 (06) : 541 - 545
  • [37] Acute subjective effects of dynorphin A(1-13) infusion in normal healthy subjects
    King, AC
    Ho, A
    Schluger, J
    Borg, L
    Kreek, MJ
    DRUG AND ALCOHOL DEPENDENCE, 1999, 54 (01) : 87 - 90
  • [38] TREATMENT OF STROKE WITH OPIATE ANTAGONISTS - EFFECTS OF EXOGENOUS ANTAGONISTS AND DYNORPHIN 1-13
    BASKIN, DS
    KURODA, H
    HOSOBUCHI, Y
    LEE, NM
    NEUROPEPTIDES, 1985, 5 (4-6) : 307 - 310
  • [39] 2D NMR studies of dynorphin A(1-13) in solution:: Potent κ opioid receptor agonist
    Renugopalakrishnan, V.
    Huang, Shaw-Guang
    Prabhakaran, M.
    PEPTIDE REVOLUTION: GENOMICS, PROTEOMICS & THERAPEUTICS, 2004, : 371 - 372
  • [40] MULTIDIMENSIONAL BEHAVIORAL-ANALYSES SHOW DYNORPHIN A-(1-13) MODULATION OF METHAMPHETAMINE-INDUCED BEHAVIORS IN MICE
    UKAI, M
    TOYOSHI, T
    KAMEYAMA, T
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 222 (01) : 7 - 12